apixaban reversal | Anticoagulation Reversal Guideline for Adults

Keyword	CPC	PCC	Volume	Score	Length of keyword
apixaban reversal	1.96	0.2	3109	20	17
apixaban	0.6	0.4	8059	29	8
reversal	1.06	0.7	1677	18	8

Keyword	CPC	PCC	Volume	Score
apixaban reversal	0.06	0.7	7797	89
apixaban reversal agent	0.46	0.6	5281	76
apixaban reversal guidelines	1.46	0.5	1804	56
apixaban reversal octaplex	0.78	0.4	9645	100
apixaban reversal litfl	0.95	0.5	2450	83
apixaban reversal wikem	2	0.7	8684	97
apixaban reversal agent uk	0.62	0.9	5440	35
apixaban reversal for surgery	1.04	1	9278	88
apixaban reversal ffp	1.87	0.4	1337	96
apixaban reversal pcc	0.32	0.6	6776	85
apixaban reversal drug	0.11	0.6	8951	79
apixaban reversal andexxa	0.09	0.8	7875	12
apixaban reversal kcentra	0.83	0.5	4786	61
apixaban reversal guidelines uk	0.6	0.6	8841	68
reversal agent for rivaroxaban and apixaban	1.76	0.4	2560	31
does apixaban have a reversal agent	1.29	0.7	3211	29
what is the reversal agent for apixaban	0.92	0.5	4243	50

Search Results related to apixaban reversal on Search Engine

Anticoagulation Reversal Guideline for Adults - American …
heart.org

https://www.heart.org/-/media/files/professional/quality-improvement/hemorrhagic--stroke/hemorrhagic-stroke-toolkit-page/5_18_2021/anticoagulation-reversal-guideline-for-adults-5182021.pdf?la=en

WEBDirect Oral Anticoagulants (Apixaban, Betrixaban, Edoxaban, Rivaroxaban) 11-13 Fondaparinux 14 Intravenous Direct Thrombin Inhibitors (Argatroban, Bivalirudin) 15 Thrombolytics (Alteplase, Tenecteplase) 16 Antiplatelets 17 Appendix A. Andexanet Alfa (Andexxa®) Restriction Criteria 18

DA: 39 PA: 65 MOZ Rank: 66 Up or Down: Up

Anticoagulant reversal - EMCrit Project
emcrit.org

https://emcrit.org/ibcc/reverse/

WEBSep 25, 2021 · Possible indications for reversal: (1) Major bleeding or planned high-risk procedure. (2) Last dose taken within <12-24 hours (with normal renal function). For patients with intracranial hemorrhage, reversal may be considered if the last dose was within <5 half-lives (i.e., within the past 2-4 days. (Albin 2022)

DA: 90 PA: 16 MOZ Rank: 94 Up or Down: Up

ANTICOAGULANTS: THE GUIDE TO REVERSAL - OHSU
ohsu.edu

https://www.ohsu.edu/sites/default/files/2019-08/Reversing%20Antithrombotic%20Therapy.pdf

WEB• Low dose: Apixiban 5mg or less dose or rivaroxaban 10mg or less dose; Apixaban and rivaroxaban any dose over 8 hours after taking • High dose: Apixaban over 5 mg dose within last 8 hours, Rivaroxaban over 10mg dose within last 8 hours

DA: 3 PA: 75 MOZ Rank: 96 Up or Down: Up

Emergency Reversal of Anticoagulation - PMC - National Center …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754204/

WEBAug 6, 2019 · Apixaban (Eliquis), rivaroxaban (Xarelto), edoxaban (Savaysa), and betrixaban (Bevyxxa) reversibly and competitively inhibit free and clot-bound factor Xa. With the exception of betrixaban, which has a more limited scope of indications, Xa agents are FDA-approved for stroke and systemic embolism prevention in patients with nonvalvular …

DA: 88 PA: 18 MOZ Rank: 19 Up or Down: Up

Reversal of direct oral anticoagulants: Highlights from the
ccjm.org

https://www.ccjm.org/content/88/2/98

WEBFeb 1, 2021 · It is approved for reversal of apixaban and rivaroxaban in cases of bleeding. 8 However, its use to reverse the effects of edoxaban and betrixaban is currently off-label, as larger studies are still needed to determine its efficacy and safety for this use. Off-label use of hemostatic agents.

DA: 87 PA: 14 MOZ Rank: 25 Up or Down: Up

Management of bleeding in patients receiving direct oral ... - UpToDate
uptodate.com

https://www.uptodate.com/contents/management-of-bleeding-in-patients-receiving-direct-oral-anticoagulants

WEBFeb 16, 2024 · Management of bleeding in individuals who are receiving a direct oral anticoagulant (DOAC) can be challenging because routine coagulation tests cannot generally be used to determine the degree of anticoagulation, and some of the reversal agents are difficult to access and may be prothrombotic.

DA: 71 PA: 43 MOZ Rank: 27 Up or Down: Up

Practical Guide for Anticoagulant and Antiplatelet Reversal in …
nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963371/

WEBFeb 11, 2023 · Direct oral anticoagulants (DOACs) include rivaroxaban, apixaban, edoxaban, and betrixaban. Direct thrombin inhibitors (DTIs) include argatroban, bivalirudin, and dabigatran. DOACs are associated with lower rates of fatal, life-threatening, and significant bleeding risks compared to those of warfarin.

DA: 58 PA: 57 MOZ Rank: 12 Up or Down: Up

Andexanet Alfa for Anticoagulant Reversal - American College of …
acc.org

https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2021/03/26/18/33/andexanet-alfa-for-anticoagulant-reversal

WEBMar 26, 2021 · Andexanet alfa is approved for patients taking apixaban or rivaroxaban who require reversal of anticoagulation due to life-threatening or uncontrolled bleeding.

DA: 52 PA: 54 MOZ Rank: 47 Up or Down: Up

Specific Antidotes for Direct Oral Anticoagulant Reversal
ahajournals.org

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.041687

WEBOct 28, 2019 · The aim of reversal is to reduce anticoagulant activity below a safety hemostatic threshold, usually defined by international normalized ratio <1.3–1.5 for vitamin K antagonists and 50 ng/mL for DOACs. 4 After reversal, dabigatran activity was nearly undetectable in 99.4% of the patients in RE-VERSE AD, whereas more than a quarter of …

DA: 55 PA: 43 MOZ Rank: 61 Up or Down: Up

ACC Consensus on Management of Anticoagulant-Related Bleeding
acc.org

https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2020/07/10/11/26/2020-acc-expert-consensus-decision-pathway-on-bleeding

WEBJul 14, 2020 · Reversal agents should not be used for most patients with a nonmajor bleeding event. For patients taking warfarin or other VKA, use of a four-factor prothrombin complex concentrate (4f-PCC) is advised for reversal. Fresh frozen plasma can be used if a 4f-PCC is not available.

DA: 68 PA: 32 MOZ Rank: 99 Up or Down: Up